Items Tagged ‘immunotherapy’

July 24th, 2017

Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas

By

Donald M. O’Rourke, MD Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat […]

View full entry

Tags: Brain Cancer, brain tumor, CAR T Cells, glioblastoma, immunotherapy, News


July 11th, 2017

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

By

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking place June 28 through July 1, 2017 in Barcelona, Spain. AM0010 is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced cancer patients and in a […]

View full entry

Tags: AM0010, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin


July 6th, 2017

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients

By

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone, […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, News, nivolumab, nsclc, opdivo, Precision Cancer Medicine


June 22nd, 2017

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer

By

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, durvalumab, immunotherapy, News, precision medicine, Triple Negative Breast Cancer


June 15th, 2017

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) report that Keytruda is now associated with a 30% improvement in survival when used as initial treatment for advanced […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, PD-1, pembrolizumab, precison medicine, Yervoy


June 2nd, 2017

Radiation Therapy can Enhance Effectiveness of Immunotherapy in People With Advanced Lung Cancer

By

UCLA RESEARCH ALERT FINDINGS A new study by UCLA scientists has found that the breakthrough immunotherapy drug Keytruda (pembrolizumb)  can be more effective in improving survival in people with non-small cell lung cancer (NSCLC) if they have previously received radiation therapy, compared to those without a history of radiation treatment. The findings are important as […]

View full entry

Tags: immunotherapy, Keyturda, Lung Cancer, Lung Cancer - Non-Small Cell, NCSLC, News, PD-1, pembrolizumb, radiation


May 11th, 2017

FDA Approves Imfinzi for Treatment of Urothelial Cancer

By

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of treatment with that chemotherapy. Bladder cancer is the most common type […]

View full entry

Tags: Bladder Cancer, durvalumab, Imfinzi, immunotherapy, News, PD-1, urothelial carcinoma


May 8th, 2017

First New Drug for Liver Cancer in a Decade: Stivarga

By

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s indication marks the first FDA-approved treatment for a liver cancer in almost a decade. Stivarga is an oral […]

View full entry

Tags: immunotherapy, Liver Cancer, News, regorafenib, Stivarga


May 4th, 2017

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma

By

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76% of patients with Diffuse Large B-Cell Lymphoma (DLBCL) responded to treatment, 47% achieving a complete remissions (CR). About axicabtagene ciloleucel Axicabtagene […]

View full entry

Tags: CAR T, HD, HNL, immunotherapy, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma


April 21st, 2017

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed

By

Small, phase one trial of a dendritic cell vaccine supports further study in larger trials A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases, researchers at the Duke […]

View full entry

Tags: General, glioblastoma, immunotherapy, News, Other News Topics (not Types of Cancer)


April 19th, 2017

Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

By

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy (ipilumamab) and Opdivo (nivolumab) combinations has just been reported.  The two-year survival rates were 64% for the Opdivo plus Yervoy combination, 59% for Opdivo alone and 45% for Yervoy alone. About Opdivo Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is […]

View full entry

Tags: immunotherapy, Melanoma, News, opdivo, PD1


April 18th, 2017

Tagrisso Approved for Treatment of Certain Lung Cancers

By

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Lung cancer remains the leading […]

View full entry

Tags: immunotherapy, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, tagrisso


March 23rd, 2017

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

By

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20 percent of cancers diagnosed worldwide. The trial is called DART, […]

View full entry

Tags: All Cancer Types, General, immunotherapy, keytruda, Neuroblastoma, News, Other News Topics (not Types of Cancer), Retinoblastoma, Sarcoma, Vaginal Cancer


February 16th, 2017

FDA Approves Opdivo for Treatment of Bladder Cancer

By

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing chemotherapy. Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. […]

View full entry

Tags: Bladder Cancer, immunotherapy, News, nivolumab, PD-1


February 6th, 2017

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer

By

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments. About Gastric Cancer Gastric cancer refers to cancer of the […]

View full entry

Tags: Gastric Cancer, immunotherapy, News, nivolumab, opdivo, precision medicine